Ignite Creation Date:
2025-12-24 @ 5:58 PM
Ignite Modification Date:
2026-01-04 @ 3:39 PM
Study NCT ID:
NCT02957968
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-28
First Post:
2016-11-03
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Sponsor:
Virginia Commonwealth University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-01-24
Start Date Type:
ACTUAL
Primary Completion Date:
2022-08-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2016-11-03
First Submit QC Date:
None
Study First Post Date:
2016-11-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-08-07
Results First Submit QC Date:
None
Results First Post Date:
2023-11-09
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-11
Last Update Post Date:
2025-08-28
Last Update Post Date Type:
ESTIMATED